Amyloid-β1-42 Disrupts Synaptic Plasticity by Altering Glutamate Recycling at the Synapse

Journal of Alzheimer's Disease

Volumn 45, Issue 2, 2015, Pages 449-456

  Varga, Edina ^a   Juhász, Gábor ^a   Bozsó, Zsolt ^a   Penke, Botond ^a   Fülöp, Lívia ^a   Szegedi, Viktor ^b  

^a UNIVERSITY OF SZEGED   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Alzheimer's disease; glutamate scavenger; glutamate reuptake; long term potentiation; NR2B; TBOA

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; ASPARTIC ACID; DEXTRO LEVO THREO BETA BENZYLOXYASPARTATE; GLUTAMIC ACID; IFENPRODIL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PYRUVATE SODIUM; SCAVENGER; UNCLASSIFIED DRUG; ALANINE AMINOTRANSFERASE; AMINO ACID RECEPTOR BLOCKING AGENT; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); BENZYLOXYASPARTATE; PEPTIDE FRAGMENT; PIPERIDINE DERIVATIVE; PYRUVIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; LONG TERM POTENTIATION; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; SYNAPSE; ANALYSIS OF VARIANCE; ANIMAL; BAGG ALBINO MOUSE; BIOPHYSICS; CYTOLOGY; DRUG EFFECTS; ELECTROSTIMULATION; HIPPOCAMPUS; IN VITRO STUDY; METABOLISM; NERVE CELL NETWORK; PATCH CLAMP TECHNIQUE;

ALANINE TRANSAMINASE; AMYLOID BETA-PEPTIDES; ANALYSIS OF VARIANCE; ANIMALS; ASPARTIC ACID; BIOPHYSICS; ELECTRIC STIMULATION; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; HIPPOCAMPUS; IN VITRO TECHNIQUES; MICE; MICE, INBRED BALB C; NERVE NET; NEURONAL PLASTICITY; PATCH-CLAMP TECHNIQUES; PEPTIDE FRAGMENTS; PIPERIDINES; PYRUVIC ACID; SYNAPSES;

EID: 84925354757     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-142367     Document Type: Article

References (46)

1. Kuo YM, Emmerling MR, Vigo-Pelfrey C, Kasunic TC, Kirkpatrick JB, Murdoch GH, Ball MJ, Roher AE (1996) Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J Biol Chem 271, 4077-4081.
2. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J (1999) Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155, 853-862.
3. Rowan MJ, Klyubin I, Cullen WK, Anwyl R (2003) Synaptic plasticity in animal models of early Alzheimer's disease. Philos Trans R Soc Lond B Biol Sci 358, 821-828.
4. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539.
5. Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ (2011) Soluble Abeta oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci 31, 6627-6638.
6. Fulop L, Mandity IM, Juhasz G, Szegedi V, Hetenyi A,Weber E, Bozso Z, Simon D, Benko M, Kiraly Z, Martinek TA (2012) A foldamer-dendrimer conjugate neutralizes synaptotoxic beta-amyloid oligomers. PLoS One 7, e39485.
7. Bozso Z, Penke B, Simon D, Laczko I, Juhasz G, Szegedi V, Kasza A, Soos K, Hetenyi A, Weber E, Tohati H, Csete M, Zarandi M, Fulop L (2010) Controlled in situ preparation of A beta(1-42) oligomers from the isopeptide "iso-A beta(1-42)", physicochemical and biological characterization. Peptides 31, 248-256.
8. Hu NW, Klyubin I, Anwyl R, Rowan MJ (2009) GluN2B subunit-containing NMDA receptor antagonists prevent Abeta-mediated synaptic plasticity disruption in vivo. Proc Natl Acad Sci U S A 106, 20504-20509.
9. Zhang J,Wang C, Deng T, Xue Z, Chen X, Chang L, Wang Q (2013) The preventive effect of NR2B and NR2D-containing NMDAR antagonists on Abeta-induced LTP disruption in the dentate gyrus of rats. Metab Brain Dis 28, 697-704.
10. Klyubin I, Betts V, Welzel AT, Blennow K, Zetterberg H, Wallin A, Lemere CA, Cullen WK, Peng Y, Wisniewski T, Selkoe DJ, Anwyl R,Walsh DM, Rowan MJ (2008) Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: Prevention by systemic passive immunization. J Neurosci 28, 4231-4237.
11. Olsen KM, Sheng M (2012) NMDA receptors and BAX are essential for Abeta impairment of LTP. Sci Rep 2, 225.
12. Koh JY, Yang LL, Cotman CW (1990) Beta-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res 533, 315-320.
13. Pomara N, Singh R, Deptula D, Chou JC, Schwartz MB, LeWitt PA (1992) Glutamate and other CSF amino acids in Alzheimer's disease. Am J Psychiatry 149, 251-254.
14. Harkany T, Abraham I, Timmerman W, Laskay G, Toth B, Sasvari M, Konya C, Sebens JB, Korf J, Nyakas C, Zarandi M, Soos K, Penke B, Luiten PG (2000) beta-amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis. Eur J Neurosci 12, 2735-2745.
15. Chen KH, Reese EA, Kim HW, Rapoport SI, Rao JS (2011) Disturbed neurotransmitter transporter expression in Alzheimer's disease brain. J Alzheimers Dis 26, 755-766.
16. Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D (2009) Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 62, 788-801.
17. Matos M, Augusto E, Oliveira CR, Agostinho P (2008) Amyloid-beta peptide decreases glutamate uptake in cultured astrocytes: Involvement of oxidative stress and mitogen-activated protein kinase cascades. Neuroscience 156, 898-910.
18. Mura E, Zappettini S, Preda S, Biundo F, Lanni C, Grilli M, Cavallero A, Olivero G, Salamone A, Govoni S, Marchi M (2012) Dual effect of beta-amyloid on alpha7 and alpha4beta2 nicotinic receptors controlling the release of glutamate, aspartate and GABA in rat hippocampus. PLoS One 7, e29661.
19. Matos M, Augusto E, Machado NJ, dos Santos-Rodrigues A, Cunha RA, Agostinho P (2012) Astrocytic adenosine A2A receptors control the amyloid-beta peptide-induced decrease of glutamate uptake. J Alzheimers Dis 31, 555-567.
20. Liu DD, Yang Q, Li ST (2013) Activation of extrasynaptic NMDA receptors induces LTD in rat hippocampal CA1 neurons. Brain Res Bull 93, 10-16.
21. Hardingham GE, Fukunaga Y, Bading H (2002) Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci 5, 405-414.
22. Varga E, Juhász G, Bozsó Z, Penke B, Fülöp L, Szegedi V (2014) Abeta(1-42) enhances neuronal excitability in the CA1 via NR2B subunit-containing NMDA receptors. Neural Plast 2014, 584314.
23. Juhasz G, Marki A, Vass G, Fulop L, Budai D, Penke B, Falkay G, Szegedi V (2009)Anintraperitoneally administered pentapeptide protects against Abeta (1-42) induced neuronal excitation in vivo. J Alzheimers Dis 16, 189-196.
24. Xu Y, Cao DH, Wu GM, Hou XY (2014) Involvement of P38MAPK activation by NMDA receptors and non-NMDA receptors in amyloid-beta peptide-induced neuronal loss in rat hippocampal CA1 and CA3 subfields. Neurosci Res 85, 51-57.
25. Dinamarca MC, Rios JA, Inestrosa NC (2012) Postsynaptic receptors for amyloid-beta oligomers as mediators of neuronal damage in Alzheimer's disease. Front Physiol 3, 464.
26. Tackenberg C, Grinschgl S, Trutzel A, Santuccione AC, Frey MC, Konietzko U, Grimm J, Brandt R, Nitsch RM (2013)NMDAreceptor subunit composition determines beta-amyloid-induced neurodegeneration and synaptic loss. Cell Death Dis 4, e608.
27. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL (2007) Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27, 2866-2875.
28. Larson M, Sherman MA, Amar F, Nuvolone M, Schneider JA, Bennett DA, Aguzzi A, Lesne SE (2012) The complex PrP(c)-Fyn couples human oligomeric Abeta with pathological tau changes in Alzheimer's disease. J Neurosci 32, 16857-16871a.
29. Um JW, Kaufman AC, Kostylev M, Heiss JK, Stagi M, Takahashi H, Kerrisk ME, Vortmeyer A, Wisniewski T, Koleske AJ, Gunther EC, Nygaard HB, Strittmatter SM (2013) Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer abeta oligomer bound to cellular prion protein. Neuron 79, 887-902.
30. Um JW, Nygaard HB, Heiss JK, Kostylev MA, Stagi M, Vortmeyer A, Wisniewski T, Gunther EC, Strittmatter SM (2012) Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci 15, 1227-1235.
31. Anderson CM, Swanson RA (2000) Astrocyte glutamate transport: Review of properties, regulation, and physiological functions. Glia 32, 1-14.
32. Masliah E, Alford M, Mallory M, Rockenstein E, Moechars D, Van Leuven F (2000) Abnormal glutamate transport function in mutant amyloid precursor protein transgenic mice. Exp Neurol 163, 381-387.
33. Noda M, Nakanishi H, Akaike N (1999) Glutamate release from microglia via glutamate transporter is enhanced by amyloid-beta peptide. Neuroscience 92, 1465-1474.
34. Jacob CP, Koutsilieri E, Bartl J, Neuen-Jacob E, Arzberger T, Zander N, Ravid R, Roggendorf W, Riederer P, Grunblatt E (2007) Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's disease. J Alzheimers Dis 11, 97-116.
35. Scott HL, Pow DV, Tannenberg AE, Dodd PR (2002) Aberrant expression of the glutamate transporter excitatory amino acid transporter 1 (EAAT1) in Alzheimer's disease. J Neurosci 22, RC206.
36. Rammes G, Hasenjager A, Sroka-Saidi K, Deussing JM, Parsons CG (2011) Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of beta-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices. Neuropharmacology 60, 982-990.
37. Ronicke R,Mikhaylova M, Ronicke S, Meinhardt J, Schroder UH, Fandrich M, Reiser G, Kreutz MR, Reymann KG (2011) Early neuronal dysfunction by amyloid beta oligomers depends on activation of NR2B-containing NMDA receptors. Neurobiol Aging 32, 2219-2228.
38. Harney SC, Jane DE, Anwyl R (2008) Extrasynaptic NR2D-containing NMDARs are recruited to the synapse during LTP of NMDAR-EPSCs. J Neurosci 28, 11685-11694.
39. Foster KA, McLaughlin N, Edbauer D, Phillips M, Bolton A, Constantine-Paton M, Sheng M (2010) Distinct roles of NR2A and NR2B cytoplasmic tails in long-term potentiation. J Neurosci 30, 2676-2685.
40. Hasegawa Y, Mukai H, Asashima M, Hojo Y, Ikeda M, Komatsuzaki Y, Ooishi Y, Kawato S (2014) Acute modulation of synaptic plasticity of pyramidal neurons by activin in adult hippocampus. Front Neural Circuit 8, 56.
41. Chen J, Herrup K (2012) Glutamine acts as a neuroprotectant against DNA damage, beta-amyloid and H2O2-induced stress. PLoS One 7, e33177.
42. Marosi M, Fuzik J, Nagy D, Rakos G, Kis Z, Vecsei L, Toldi J, Ruban-Matuzani A, Teichberg VI, Farkas T (2009) Oxaloacetate restores the long-term potentiation impaired in rat hippocampus CA1 region by 2-vessel occlusion. Eur J Pharmacol 604, 51-57.
43. Campos F, Sobrino T, Ramos-Cabrer P, Argibay B, Agulla J, Perez-Mato M, Rodriguez-Gonzalez R, Brea D, Castillo J (2011) Neuroprotection by glutamate oxaloacetate transaminase in ischemic stroke: An experimental study. J Cereb Blood Flow Metab 31, 1378-1386.
44. Boyko M, Melamed I, Gruenbaum BF, Gruenbaum SE, Ohayon S, Leibowitz A, Brotfain E, Shapira Y, Zlotnik A (2012) The effect of blood glutamate scavengers oxaloacetate and pyruvate on neurological outcome in a rat model of subarachnoid hemorrhage. Neurotherapeutics 9, 649-657.
45. Mitani H, Shirayama Y, Yamada T, Maeda K, Ashby CR Jr, Kawahara R (2006) Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog Neuropsychopharmacol Biol Psychiatry 30, 1155-1158.
46. Shinohe A, Hashimoto K, Nakamura K, Tsujii M, Iwata Y, Tsuchiya KJ, Sekine Y, Suda S, Suzuki K, Sugihara G, Matsuzaki H, Minabe Y, Sugiyama T, Kawai M, Iyo M, Takei N, Mori N (2006) Increased serum levels of glutamate in adult patients with autism. Prog Neuropsychopharmacol Biol Psychiatry 30, 1472-1477.